Evidence map›Paper›PMID 40314901›Full record

ArticleAnnals of surgical oncology2025

Characterization of the Germline Pathogenic Mutational Landscape and Oncologic Outcomes Among 877 Patients with Invasive Lobular Carcinoma.

Victoria D Huynh, Jason Mouabbi, Henry M Kuerer, Kerollos Nashat Wanis, Hiam M Abdel-Salam, Angelica M Gutierrez, Helen M Johnson, Anthony Lucci, Kelly K Hunt, Banu K Arun

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Victoria D HuynhDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jason MouabbiDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Henry M KuererDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. hkuerer@mdanderson.org.
Kerollos Nashat WanisDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hiam M Abdel-SalamClinical Cancer Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Angelica M GutierrezClinical Cancer Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Helen M JohnsonDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anthony LucciDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kelly K HuntDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Banu K ArunDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThere is a paucity of literature on germline pathogenic variants (gPVs) in patients with invasive lobular carcinoma (ILC). This study characterizes the landscape and compares clinicopathologic variables and treatment outcomes between those with and without gPVs.

methodsA prospectively maintained institutional database was used to identify all patients diagnosed with nonmetastatic ILC who had germline genetic testing. Clinicopathologic characteristics and time to recurrence, contralateral cancer, and death were compared for patients with and without gPVs. Conditional hazard ratios, computed by Cox proportional hazards models, described associations between clinicopathologic factors, including gPV status, and cancer events.

resultsOf 4398 patients with nonmetastatic ILC seen between 1989 and 2024, 1170 patients were evaluated by genetic counselors; 877 underwent genetic testing. 10% (83/877) had gPVs, of whom 87% (72/83) had gPVs in known breast cancer predisposition genes; 13% had gPVs in preliminary evidence genes or genes not previously known to be breast cancer associated. Patients with gPVs were more likely to be younger than 40 years, be premenopausal, have high grade and triple-negative receptor status, and undergo mastectomy compared with those without gPV (p < 0.01). At median follow-up of 80 months (interquartile range, IQR 38-135 years), there was no significant difference in the time to contralateral breast cancer, distant or local-regional recurrence, and survival among patients with and without gPVs.

conclusionIn this large single-institutional analysis, patients with ILC had a distinct landscape of gPVs in breast cancer and non-breast cancer predisposition genes. A significant proportion of patients with ILC have gPVs, and these findings have potentially actionable implications.

Indexed as

Biomarkers, TumorBreast NeoplasmsCarcinoma, LobularGenetic Predisposition to DiseaseGerm-Line MutationNeoplasm Recurrence, LocalAdultAgedFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm InvasivenessPrognosisProspective StudiesSurvival RateBiomarkers, TumorBreast cancerGenetic mutationsGermline pathogenic variantsHereditary lobular breast cancerInvasive lobular carcinomaOutcomesSurvival

Identifiers

PMID40314901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.